PYC Therapeutics completes dosing in RP11 patient cohort 3

PYC Therapeutics (ASX: $PYC) has completed dosing in patient cohort 3 of the ongoing Single Ascending Dose (SAD) study for its drug candidate targeting Retinitis Pigmentosa type 11 (RP11). The completion of dosing marks a significant milestone in the clinical trial, as the company progresses towards initiating an open-label Multiple Ascending Dose (MAD) study for RP11 patients. The outcome of these studies will inform the design of a registrational trial intended to support a New Drug Application expected to commence next year.

Executive Commentary on RP11 Program

The completion of dosing in patient cohort 3 of the Single Ascending Dose study represents a crucial step forward in our efforts to develop a first-in-class precision medicine for patients with RP11. We are encouraged by the progress and are now preparing for the initiation of an open-label Multiple Ascending Dose study, which will provide further insights into the potential of our drug candidate. The data from these studies, along with the ongoing Natural History study in RP11 patients, will guide the design of a registrational trial aimed at establishing our drug candidate as the first treatment option for this blinding eye disease. We are committed to advancing our RP11 program and look forward to the potential impact our therapy may have on patients' lives in the future.

Summary of PYC Therapeutics Announcement

PYC Therapeutics (ASX: $PYC) has achieved a significant milestone by completing dosing in patient cohort 3 of the Single Ascending Dose study for its RP11 drug candidate. The company is now preparing to initiate an open-label Multiple Ascending Dose study, with the aim of gathering further data to support the development of a registrational trial. The RP11 program targets a blinding disease of childhood with a significant unmet medical need, and the completion of dosing marks a positive step towards addressing this challenge. With the potential to become the first treatment option for RP11 patients, PYC's drug candidate holds promise in addressing a currently underserved patient population. The company's commitment to advancing precision medicines for genetic diseases underscores its dedication to making a meaningful difference in patients' lives.